Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 6/20 | 0.52 |
| ▸ | DAO | P14920 | 1/20 | 0.52 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.40 |
| ▸ | ALPL | P05186 | 1/20 | 0.39 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | GABRR2 | P28476 | 1/20 | 0.37 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.37 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1371875 | 0.98 | HCAR2 (0.50) | HCAR2DAOGABRR1CCNA2CDK2 | |
| SCHEMBL12174907 | 0.84 | HCAR2 (0.47) | HCAR2DAOCCNA2CDK2CCNA1 | |
| SCHEMBL6507956 | 0.82 | HCAR2 (0.46) | HCAR2DAOCCNA2CDK2CCNA1 | |
| SCHEMBL855024 | 0.81 | HCAR2 (0.48) | HCAR2DAOCCNA2CDK2CCNA1 | |
| SCHEMBL14387809 | 0.79 | THRB (0.43) | HCAR2DAOGABRR1ALDH1A1KDM4E | |
| SCHEMBL3587984 | 0.79 | KDM4E (0.48) | HCAR2DAOCCNA2CDK2CCNA1 | |
| SCHEMBL12158535 | 0.79 | HCAR2 (0.43) | HCAR2DAOCCNA2CDK2CCNA1 | |
| SCHEMBL8720083 | 0.78 | SMN1; SMN2 (0.51) | HCAR2DAOALDH1A1KDM4EPOLB | |
| SCHEMBL27491990 | 0.78 | ALPL (0.42) | HCAR2DAOCCNA2CDK2CCNA1 | |
| SCHEMBL5989046 | 0.78 | HCAR2 (0.37) | HCAR2DAOGABRR1ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-9624200-B2 | Therapeutic piperazines | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2017-04-18 | — | — | US | disclosed |
| US-20150087645-A1 | THERAPEUTIC PIPERAZINES | HELICON THERAPEUTICS, INC. | 2015-03-26 | — | — | US | disclosed |
| US-8927546-B2 | Therapeutic piperazines | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2015-01-06 | — | — | US | disclosed |
| EP-2643000-A2 | THERAPEUTIC PIPERAZINES | Dart Neuroscience (Cayman) Ltd (KY) | 2013-10-02 | — | — | EP | disclosed |
| US-8178681-B2 | methyl 3-methyl-2-{[2-oxo-1-(2-oxo-ethyl)-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-butyrate; cannabinoid receptor agonist; antiinflammatory agent, immunostimulant, analgesic; atopic dermatitis; excellent in photostability, and have excellent transdermal and oral absorbency | SHIONOGI & CO., LTD. (JP) | 2012-05-15 | — | — | US | disclosed |
| WO-2012040258-A2 | THERAPEUTIC PIPERAZINES | HELICON THERAPEUTICS, INC. (US) | 2012-03-29 | — | — | WO | disclosed |
| US-20110065691-A1 | THERAPEUTIC PIPERAZINES | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2011-03-17 | — | — | US | disclosed |
| CN-1209807-A | 1-pyrazol-3-yl-ethyl-4-indol-3-yl piperdine as medicine acting on central nervous system | MERCK PATENT AG (DE) | 1999-03-03 | — | — | CN | disclosed |
| EP-0879234-A1 | 1-PYRAZOL-3-YL-ETHYL-4-INDOL-3-YL-PIPERIDINE USED AS MEDICINE ACTING ON THE CENTRAL NERVOUS SYSTEM | MERCK PATENT GmbH (DE) | 1998-11-25 | — | — | EP | disclosed |
| WO-1997027186-A1 | 1-PYRAZOL-3-YL-ETHYL-4-INDOL-3-YL-PIPERIDINE USED AS MEDICINE ACTING ON THE CENTRAL NERVOUS SYSTEM | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 1997-07-31 | — | — | WO | disclosed |
| US-5340815-A | Inhibitors of 5-lipoxygenase and/or cyclooxygenase | WARNER-LAMBERT COMPANY (US) | 1994-08-23 | — | — | US | disclosed |
| EP-0569491-A4 | 2-SUBSTITUTED-4,6-DI-TERTIARY-BUTYL-5-HYDROXY-1,3-PYRIMIDINES USEFUL AS ANTIINFLAMMATORY AGENTS | — | 1993-11-24 | — | — | EP | disclosed |
| EP-0569491-A1 | 2-SUBSTITUTED-4,6-DI-TERTIARY-BUTYL-5-HYDROXY-1,3-PYRIMIDINES USEFUL AS ANTIINFLAMMATORY AGENTS | WARNER-LAMBERT COMPANY (US) | 1993-11-18 | — | — | EP | disclosed |
| WO-1992013536-A1 | 2-SUBSTITUTED-4,6-DI-TERTIARY-BUTYL-5-HYDROXY-1,3-PYRIMIDINES USEFUL AS ANTIINFLAMMATORY AGENTS | WARNER-LAMBERT COMPANY (US) | 1992-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150087645-A1 | THERAPEUTIC PIPERAZINES | PDE4A, PDE4B, PDE4D | HCAR2 893/4885DAO 2105/4885GABRR1 171/4885 |
| US-20110065691-A1 | THERAPEUTIC PIPERAZINES | PDE4A, PDE4B, PDE4D | HCAR2 893/4885DAO 2105/4885GABRR1 171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.